- Q4 2023 Altimmune Inc Earnings Call TranscriptMar 27, 2024MXN213Earnings
- Altimmune Inc Conference Call TranscriptDec 01, 2023
- Q3 2023 Altimmune Inc Earnings Call TranscriptNov 07, 2023MXN48.1Earnings
- Altimmune Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Altimmune Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q2 2023 Altimmune Inc Earnings Call TranscriptAug 10, 2023MXN53.5Earnings
- Altimmune Inc at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Altimmune Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Q1 2023 Altimmune Inc Earnings Call TranscriptMay 11, 2023MXN107.05Earnings
- Altimmune Inc Conference Call TranscriptMar 21, 2023
- Q4 2022 Altimmune Inc Earnings Call TranscriptFeb 28, 2023MXN212Earnings
- Altimmune Inc Topline Results of Pemvidutide in Subjects with NAFLD Call TranscriptDec 20, 2022
- Altimmune Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Q3 2022 Altimmune Inc Earnings Call TranscriptNov 10, 2022MXN193.3Earnings
- Altimmune Inc at H C Wainwright Hepatitis B Virus (HBV) Virtual Conference TranscriptOct 18, 2022
- Altimmune Inc Conference Call TranscriptSep 14, 2022
- Q2 2022 Altimmune Inc Earnings Call TranscriptAug 11, 2022MXN260Earnings
- Altimmune Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Q1 2022 Altimmune Inc Earnings Call TranscriptMay 12, 2022MXN83 (-6.00%)Earnings
- Q4 2021 Altimmune Inc Earnings Call TranscriptMar 15, 2022MXN155.4Earnings
- Q3 2021 Altimmune Inc Earnings Call TranscriptNov 10, 2021MXN219Earnings
- Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 12, 2021
- Altimmune Inc to Host Key Opinion Leader Call on Pemvidutide Phase 1 Clinical Trial Results - Conference Call TranscriptSep 30, 2021
- Altimmune Inc to Discuss the 12-Week Data from Phase 1 Clinical Trial of ALT-801 - Conference Call TranscriptSep 28, 2021
- Q2 2021 Altimmune Inc Earnings Call TranscriptAug 11, 2021MXN230 (+15.00%)Earnings
- Altimmune Inc Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers Conference Call TranscriptJun 16, 2021
- Q1 2021 Altimmune Inc Earnings Call TranscriptMay 17, 2021MXN273Earnings
- Altimmune Inc to Present AdCOVIDâ„¢ intranasal COVID-19 at the World Vaccine Congress TranscriptMay 04, 2021
- Q4 2020 Altimmune Inc Earnings Call TranscriptFeb 25, 2021MXN361 (-9.98%)Earnings
- Q3 2020 Altimmune Inc Earnings Call TranscriptNov 10, 2020Earnings
- Altimmune Inc Annual Shareholders Meeting TranscriptSep 24, 2020
- Q2 2020 Altimmune Inc Earnings Call TranscriptAug 12, 2020Earnings
- Altimmune Inc Acceptance of IND for Covid-19 Therapeutic Testing - Call TranscriptJun 01, 2020
- Q1 2020 Altimmune Inc Earnings Call TranscriptMay 14, 2020Earnings
- Q4 2019 Altimmune Inc Earnings Call TranscriptMar 27, 2020Earnings
- Q2 2019 Altimmune Inc Earnings Call TranscriptAug 14, 2019Earnings
Altimmune Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon, everyone, and welcome to the session with Altimmune. We are fortunate to have Vipin Garg and Scott Harris here from the team.
Questions & Answers
Maybe first, we could just start with an overview of the company and with a particular focus on what you view as key value drivers over the next, let's call it, 12 to 24 months.
Okay. Yes. Perfect. Thank you for having us. So at Altimmune, we are developing peptide-based therapeutics for obesity and for liver diseases. Our most advanced asset is pemvidutide, which is a GLP-1 glucagon dual receptor agonist that we are developing for obesity and for NASH. And of course, we talk more about that. We also have immunotherapeutics and other peptide-based therapeutics that we're developing for hepatitis B.
For both of these programs, we're making
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)